Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 3, 2013, Pages 1615-1621

  Song, Jian ^a   Su, Hong ^a   Zhou, Yang Yang ^a   Guo, Liang Liang ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Meta analysis; MMP 9; Overall survival; Prognosis; Relapse free survival

Indexed keywords

EID: 84880432028     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.3.1615     Document Type: Article

References (50)

1. Beaudeux JL, Giral P, Bruckert E, et al (2004). Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med, 42, 121-31.
2. Callagy GM, Webber MJ, Pharoah PD, et al (2008). Metaanalysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer, 29, 1-10.
3. Cao DC, Liu Y, Hou Q, et al (2004). Expression and prognostic value of matrix metalloproteinase-9(MMP-9) in lymph nodenegative breast carcinoma. J Oncol, 10, 410-2.
4. Donegan WL (1997). Tumor-related prognostic factors for breast cancer. CA Cancer J Clin, 47, 28-51.
5. Duffy MJ, Maguire TM, Hill A, et al (2000). Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res, 2, 252-7.
6. Del Casar JM, Carreo G, Gonzalez LO, et al (2010). Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer. J Cancer Res Clin Oncol, 136, 1049-58.
7. Del Casar JM, Gonzalez LO, Alvarez E, et al (2009). Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat, 116, 39-52.
8. Feng Y (2008). The expression of MMP-2 and MMP-9 in breast cancer and their significance and long-term follow-up results. J Prac Oncol, 22, 331-4.
9. Fan SQ, Wei QY, Li MR, et al (2003). Expression and clinical significance of MMP-2, MMP-9, TIMP-1, and TIMP-2 in breast carcinoma. Chin J Cancer, 22, 968-73.
10. Gonzalez LO, Gonzalez RS, Marin L, et al (2010). Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumour stromal mononuclear inflammatory cells and those at the invasive front of breast carcinomas. Histopathology, 57, 862-76.
11. Gu LQ, Deng HZ, Ren SQ, et al (2009). Expression and significance of MMP-9 in breast cancer. MMJC, 11, 1-3.
12. Gonzalez LO, Corte MD, Vazquez J, et al (2008). Study of matrix metalloproteinases and their tissue inhibitors in ductal in situ carcinomas of the breast. Histopathology, 53, 403-15.
13. Guan X, Wang Y, Xie R, et al (2010). p27(Kip1) as a prognostic factor in breast cancer: a systematic review and metaanalysis. J Cell Mol Med, 14, 944-53.
14. Hao L, Zhang C, Qiu Y, et al (2007). Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett, 253, 34-42.
15. Hanemaaijer R, Verheijen JH, Magcire TM, et al (2000). Increased gelatinase and gelatinase B activities in malignant vs benign breast tumors. Int Cancer, 86, 204-7.
16. Huang ZZ, Chen WQ, Wu CX, et al (2012). Incidence and mortality of female breast cancer in China- a report from 32 Chinese cancer registries. Tumor, 32, 435-9.
17. Jemal A, Bray F, Center MM, et al (2011). Global Cancer statistics. CA Cancer J Clin, 61, 69-90.
18. Kim HS, Moon HG, Han W, et al (2012). COX2 overexpression is a prognostic marker for Stage III breast cance. Breast Cancer Res Treat, 132, 51-9.
19. Li HT, Ning LS, Zhang B (2006). Expressions and Prognosis Importance of MMP-2 and MMP-9 in Breast Cancer. J Hebei North Univ (Medical Edition), 23, 4-8.
20. Li HC, Cao DC, Liu Y, et al (2004). Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat, 88, 75-85.
21. Lepp S, Saarto T, Vehmanen L, et al (2005). Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer. Breast Cancer Res Treat, 90, 117-25.
22. Lepp S, Saarto T, Vehmanen L, et al (2004). A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res, 10, 1057-63.
23. Moore CS, Crocker SJ (2012). An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol, 180, 12-6.
24. Mendes O, Kim HT, Stoica G (2005). Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis, 22, 237-46.
25. Mohammad MA, Zeeneldin AA, Abd Elmageed ZY, et al (2012). Clinical relevance of cyclooxygenase-2 and matrix metalloproteinases (MMP-2 and MT1-MMP) in human breast cancer tissue. Mol Cell Biochem, 366, 269-75.
26. Mylona E, Nomikos A, Magkou C, et al (2007). The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology, 50, 338-47.
27. Nagase H, Woessner JF (1999). Matrix metalloproteinases. J Biol Chem, 274, 21491-4.
28. Nordmann AJ, Kasenda B, Briel M (2012). Meta-analyses: what they can and cannot do. Swiss Med Wkly, 142, w13518.
29. Oscar FG, Almudena AC, Eiro N, et al (2012). Low microvascular density at the tumor center is related to the expression of metalloproteases and their inhibitors and with the occurrence of distant metastasis in breast carcinomas. Int J Clin Oncol, 7, 1-12.
30. Peng WJ, Zhang JQ, Wang BX, et al (2012). Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer. Clin Chim Acta, 413, 1121-6.
31. Pellikainen JM, Ropponen KM, Kataja VV, et al (2004). Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res, 10, 7621-8.
32. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature forsurvival endpoints. Stat Med, 17, 2815-34
33. Quaranta M, Daniele A, Coviello M, et al (2007) MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res, 27, 3593-600.
34. Rundhaug JE (2005). Matrix metalloproteinases and angiogenesis. J Cell Mol Med, 9, 267-85.
35. Rahko E, Jukkola A, Melkko J, et al (2004). Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy. Anticancer Res, 24, 4247-53.
36. Ranogajec I, Jaki RJ, Puzovi V, et al (2012). Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9(MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol, 29,561-9.
37. Remacle AG, Nol A, Duggan C (1998) Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer, 77, 926-31.
38. Ranuncolo SM, Armanasco E, Cresta C, et al (2003). Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer, 106, 745-51.
39. Sullu Y, Demirag GG, Yildirim A, et al (2011). Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol Res Pract, 207, 747-53.
40. Scorilas A, Karameris A, Arnogiannaki N, et al (2001). Overexpression of matrix- metalloproteinase-9 in human breast cancer: a potential favourable indicator in nodenegative patients. Br J Cancer, 84, 488-96.
41. Sung H, Choi JY, Lee SA, et al (2012). The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer. BMC Cancer, 12, 193.
42. Sieuwerts AM, Meijer V, Gelder ME, et al (2005). How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res, 11, 7311-21.
43. Tian L, Wu L (2009). Expression of EGFR, MMP -9 in breast cancer and their clinical significance. Chin J Curr Adv Gen Surg, 12, 302-5.
44. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 7, 8-16.
45. Talvensaari MA, Turpeenniemi HT ( 2005). Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett, 217, 237-42.
46. Wu ZS, Wu Q, Yang JH, et al (2008). Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer, 122, 2050-6.
47. Wang LH, Liu DY, Chen YJ, et al (2002). Relationship between lymph node metastasis and the expressions of E-cadherin, N-cadherin, and matrix metalloproteinase in breast carcinoma. Ai Zheng, 21, 965-9.
48. Zhang M, Teng XD, Guo XX, et al (2012). Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancer. Breast, 17, 1-5.
49. Zhang QW, Liu L, Chen R, et al (2012). Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 13, 2903-8.
50. Zhao JX, Lin ZM, Yao HW, et al (2008). The Expression of Transferrin and MMP- 9 in Breast Cancer and Its Significance in Prognosis. Chin J Clin Oncol, 35, 22-5.